Rigel Pharmaceuticals, Inc. (RIGL) vs Savara Inc. (SVRA)
- Rigel Pharmaceuticals, Inc. RIGL 45.97 −2.71%
- Savara Inc. SVRA 4.45 −6.12%
Rigel Pharmaceuticals, Inc. and Savara Inc. are both Biotechnology companies. Savara Inc. is the larger, with a market value of $973.9M against $882.6M — 1.1× the size. Savara Inc. has negative trailing earnings, so its P/E is not meaningful; Rigel Pharmaceuticals, Inc. trades at 2.6×. Rigel Pharmaceuticals, Inc. has the higher net margin (116.3% vs 0.00%) and the higher return on invested capital (16.5% vs −12,213.2%). Across the 14 metrics below, Rigel Pharmaceuticals, Inc. leads on 13 and Savara Inc. on 1.
Valuation
Profitability
| Metric | RIGL | SVRA | Biotechnology median |
|---|---|---|---|
| Gross margin | 91.39% | 0.00% | 65.16% |
| Operating margin | 31.45% | 0.00% | 0.00% |
| Net margin | 116.30% | 0.00% | 0.00% |
| Free cash flow margin | 3.19% | 0.00% | 0.00% |
| Return on equity | 126.90% | (105.48%) | (56.36%) |
| Return on assets | 88.46% | (78.28%) | (48.04%) |
| Return on invested capital | 16.48% | (12,213.18%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack